Foley Hoag's Barbara Fiacco, Partner and Co-Chair of the firm's Intellectual Property Department and Patent, Trade Secrets and Related Rights Litigation Practice, will moderate a discussion on "Empowering Patients and Driving Pharmaceutical Progress" at the Biotechnology Innovation Organization (BIO) IP Counsels Committee Conference.
The panel will address the evolving role of patient advocacy groups and foundations during research and drug development including grants, donations and other research funding; equity positions in companies; working with patient communities on clinical trial design and recruitment; and patient representation on company advisory boards.
We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.
Foley Hoag
Email Disclaimer
Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK," you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you.
If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Foley Hoag.
